UK Pilots 'Revolutionary And Needed' Antibiotic Payment System
The UK National Health Service is to test the world's first ‘subscription’ payment model to tempt drug makers to develop new products for resistant infections.
You may also be interested in...
The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.
As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.